Development of Global Products and Commercialization of New Products

「For urine test strips, we launched the “Fully Automated Urine Analyzer US-3600 (20-rack configuration)” in February 2026 as the successor to the “US-3500MS” fully automated urine analyzer.」

「Launch of the OC Sensor R70 fecal occult blood analyser」

「For urine test strips, we launched the compact, portable “US-1300” automated urine analyzer, the successor to US-1200, as the compact model in the US series in November 2024. In December 2024, we launched the fully automated “US-3600” urine analyzer, the successor to US-3500, as the flagship model in the US series.」

「Sales of new rapid diagnostic kits, “ImmunoCatch–StrepA” and “ImmunoCatch–Adeno,” increased, bringing microbiological testing reagents to ¥2,194 million, up 3.0% year on year.」

「For OC-related reagents, we launched the OC-SENSOR Ceres fecal occult blood analyzer, which had obtained European IVDR certification, as well as fecal hemoglobin and fecal calprotectin assay reagents in November 2022. For latex reagents, we launched “LZ Test ‘Eiken’ CRP-RV” in February 2023. For immunochromatography reagents, we launched “Exdia EK Test Influenza A+B” in April 2022. For LAMP reagents, we launched the IVDR-compliant “Loopamp PURE DNA Extraction Kit” in July 2022.」

「For products related to the novel coronavirus, in addition to the LAMP-based detection reagent launched in the previous fiscal year, we launched the portable immunofluorescence analyzer “Exdia TRF Plus,” based on time-resolved fluorescence immunoassay using the fluorescent substance europium, and the SARS coronavirus antigen kit “Exdia EK Test COVID-19 Ag” in March 2022.」

「In February 2021, we launched the “US-2300 Automated Urine Analyzer” and “OC-SENSOR Ceres Fecal Occult Blood Analyzer.”」

「To address the medical need of “Near the patient,” we developed a compact, fully automated genetic testing system using the LAMP method during the current consolidated fiscal year and launched the “Fully Automated Nucleic Acid Testing Instrument Simprova,” “Simprova Respiratory Infection Panel BP,LP,MP,” and “Simprova Extraction Kit/S1” in April 2020.」

「In genetic testing reagents, we had already launched the European in vitro diagnostic “Loopamp MALARIA Pan/Pf Detection kit,” which simultaneously detects Plasmodium falciparum and all species of human malaria parasites, with the aim of overcoming malaria, one of the three major infectious diseases. In response to market demand for separate testing, we commercialized the two tests as separate kits. We also added “Loopamp MALARIA Pv detection kit,” which detects Plasmodium vivax, whose treatment differs from that for other malaria parasites, to the new product lineup.」

「In genetic testing reagents, we launched “Loopamp Aspergillus F Detection Reagent Kit” as a research-use reagent in March 2018. The kit detects the gene of Aspergillus fumigatus, the principal causative organism of aspergillosis, which accounts for 70% of isolated Aspergillus species and is highly infectious and pathogenic. In bacteriological testing reagents, we launched the standard sheep blood agar medium “POURMEDIA Tryptic Soy 5% Sheep Blood Agar” in April 2017 and “POURMEDIA Vi Haemophilus Agar” in January 2018. In response to growing focus on antimicrobial resistance (AMR), we launched “KB Disk ‘Eiken’ Tigecycline” in October 2017 to support appropriate drug selection. In immunochromatography products, we launched “ImmunoCatch Noro Plus” in August 2017.」

「Among rapid testing products based on immunochromatography, we launched “ImmunoCatch-Legionella” and “ImmunoCatch-Pneumococcus” overseas in October 2016. These products had been launched in Japan in December 2014 and January 2016, respectively, and had received favorable market responses. In addition, as measures to address antimicrobial resistance (AMR) have recently come into focus, we launched the antifungal susceptibility test “Yeast-like Fungi FP” in November 2016, the antimicrobial susceptibility test “Tigecycline FP” in November 2016, and “Metronidazole FP” in March 2017 to support the appropriate selection of antimicrobial drugs. For urinalysis instruments, we launched the portable “US-1200” automated urine analyzer, which supports a broad range of screening applications, in August 2016.」

「We advanced product improvements through technological refinement and launched “US-1200,” the successor to the “US-1000” automated urine analyzer, in August 2016. In addition, “Loopamp Pertussis Detection Reagent Kit D,” a nucleic acid kit for Bordetella pertussis using the LAMP method, was listed for reimbursement in November 2016.」

「We advanced product improvements through technological refinement and launched “US-1200,” the successor to the “US-1000” automated urine analyzer, in August 2016.」

「For rapid testing kits based on immunochromatography, we promoted sales mainly of “ImmunoCatch-Legionella” and “ImmunoCatch-Pneumococcus,” launched in January 2016, as part of the ImmunoCatch series.」

「We made the development of global products our highest priority, worked to understand market trends, strengthened and enhanced our existing lineup of major products, and advanced product development by strengthening our proprietary technologies and R&D capabilities.」